ADVANCES IN Cancer IMMUNOTHERAPY™

Identification and Management of Immune-Related Adverse Events in the Emergency Setting

William T. Durkin, Jr., MD MBA FAAEM

Past President, American Academy of Emergency Medicine

ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

Disclosures

- **No relevant financial relationships to disclose**

CTLA-4 and PD-1/PD-L1
Immune checkpoint mechanisms

- Involved in maintaining appropriate immune response
- Downregulates & prevents inappropriate activity
- Autoimmune type response
- Thinking “Chemo” will lead to incorrect AE strategy
- **Immunotherapy AEs similar to Graft versus Host disease**

Timing of irAE incidence

- Most irAEs occur within three months of treatment initiation
- irAEs can occur past treatment completion
- Some irAEs are dose-dependent
- ~10% of overall irAEs grade 3/4

Timing of irAE incidence



Timing of irAE incidence



Common medications for irAE treatment

- Corticosteroids
  - **Prednisone**
  - Dexamethasone
  - Methylprednisolone
  - Hydrocortisone
  - Cortisone
- Mycophenolate mofetil (CellCept)
  - Standard BID
- TNF inhibitors
  - Infliximab
  - Adalimumab
  - Others

sitc Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

Dermatologic Toxicity

ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

Dermatologic toxicity presentation

- Often presents ~ three weeks post-therapy initiation
- Mild – maculopapular rash with or without symptoms
  - Pruitis, burning, tightness
  - 10% - 30% TBSA
  - Limiting ADL's
  - Topical steroids, hydroxyzine, diphenhydramine
  - Cort
- Moderate – diffuse, nonlocalizing rash
  - 30% - 50% TBSA
  - Topical corticosteroids, hydroxyzine, diphenhydramine
  - Consider systemic corticosteroids if no improvement within one week (0.5 – 1mg/kg/day)

Dermatologic toxicity presentation

- Severe
  - Blisters, dermal ulceration, necrotic, bullous or hemorrhagic
  - Systemic corticosteroids 1 – 2mg/kg/day prednisone equivalent
  - Taper over one month following improvement

- Vitiligo
  - Most cases permanant
  - No treatment
  - Intra oral lesions – consider candidiasis

Stevens Johnsons Syndrome (SJS)/ TEN (Toxic Epidermal Necrolysis)







Vitiligo

sitc Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

Diarrhea/ Colitis

ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

Diarrhea/ colitis presentation

- Mild - <4 stools above baseline/day

- Treatment
  - Symptomatic: oral hydration & bland diet
  - No corticosteroids
  - Avoid medications
  - Budesonide – no significant difference

Diarrhea/ colitis presentation

- Moderate – 4-6 stools above daily baseline
  - Abdominal pain, blood or mucus in stool
  - Testing – *C. diff*, lactoferrin, O & P, stool Cx
  - Systemic corticosteroids 0.5mg/kg/day prednisone equivalent if symptoms persist > one week

Diarrhea/ colitis presentation

- Severe – >6 stools above daily baseline
  - Peritoneal signs, ileus or fever
  - Admission
  - IV hydration
  - Rule out perforation
  - Stool studies

Diarrhea/ colitis presentation

- Severe – >6 stools above daily baseline
  - Systemic corticosteroids 1-2mg/kg/day equivalent, if no perforation
    - Hold if clinically stable until stool studies available (24hrs)
  - Unstable – High dose corticosteroids: methylprednisolone 125 mg IV daily x 3 days to evaluate responsiveness
  - Consider empiric antibiotics for fever or leukocytosis
  - Infliximab 5 mg/kg if non responsive to corticosteroids
  - Consider mycophenolate mofetil for select patients

Society for Immunotherapy of Cancer
ADVANCES IN Cancer IMMUNOTHERAPY™

Hepatotoxicity

Association of Community Cancer Centers

Society for Immunotherapy of Cancer

Hepatotoxicity presentation

- 8 -12 weeks after therapy initiation
- Grade 2 toxicity
  - 2.5< AST/ALT <5 times ULN
  - 1.5< Bilirubin<3 times ULN
  - Corticosteroids 0.5-1 mg/kg/day & 1 mo. taper
- Grade ≥3 toxicity
  - Admission
  - Methylprednisolone IV 125mg/day
  - Consider mycophenolate mofetil 500mg PO Q12hrs
- Avoid alcohol & acetaminophen

Society for Immunotherapy of Cancer
ADVANCES IN Cancer IMMUNOTHERAPY™

Endocrinopathies

Association of Community Cancer Centers
Society for Immunotherapy of Cancer

Endocrinopathy presentation

- >10% all reported irAE cases
- Can arise while receiving checkpoint inhibitors
- Hypophysitis
  - 1-2 months after initiation of therapy
  - Fatigue, headaches, visual field defects
  - ACTH, TSH, FSH, LH, GH, prolactin
  - Imaging – enlarged pituitary gland
  - Corticosteroids 1 mg/kg/day, or IV dexamethasone 6 mg Q6hr x 3 days, or methylprednisolone 125 mg daily

Endocrinopathy presentation

- Hypothyroidism
  - 1 wk-19 months onset after therapy initiation
  - Appropriate levothyroxine replacement
- Hyperthyroidism
  - Check TSH level
  - Acute thyroiditis secondary to immune activation
    - Corticosteroids 1 mg/kg for symptomatic patients
- Adrenal Insufficiency
  - Admission
  - Corticosteroids 60-80 mg prednisone or equivalent

Society for Immunotherapy of Cancer
ADVANCES IN Cancer IMMUNOTHERAPY™

Pneumonitis

Association of Community Cancer Centers
Society for Immunotherapy of Cancer

Pneumonitis presentation

- Can arise during treatment with checkpoint inhibitors
- Symptomatic ~ 5 months after treatment initiation
- New cough or dyspnea
- Multiple grades
  - Grade 2
    - Admission
    - Prednisone/prednisolone
      - Taper over one month after improvement seen
  - Grade 3-4
    - Admission
    - Prednisone/prednisolone
      - Taper over six weeks

Pneumonitis presentation



sitc Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

Pancreatic irAEs

ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

Pancreatic irAE presentation

- Elevated amylase and/or lipase
  - Can arise during treatment with checkpoint inhibitors
  - Without overt pancreatitis – monitor patient
  - Symptomatic Grade 3/4 incidences – hold therapy

- New onset diabetes with diabetic ketoacidosis
  - Normal ED treatment
  - Aggressive treatment of DKA

sitc Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

Renal insufficiency

ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

Renal insufficiency presentation

- <1% of overall irAE cases
- 10-12 months after initiation of treatment
- Grade 1: up to 1.5x baseline
- Grade 2/3: 1.5 - 6x baseline
- Full recovery with high dose corticosteroids.
  - (>40 mg/day)

Opthalmolgic irAEs

Opthalmologic irAE presentation

- <1% of overall irAE cases
- Episcleritis
- Uveitis
- Conjunctivitis
- Topical corticosteroids – prednisolone acetate 1%

Opthalmologic irAE presentation



Opthalmologic irAE presentation



Opthalmologic irAE presentation

sitc Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

Rare irAEs

ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

Rare irAE presentation

- <1% of overall irAE cases
  - Red cell aplasia
  - Thrombocytopenia
  - Hemophilia A
  - Gullian-Barre syndrome
  - Myasthenia gravis
  - Posterior reversible encephalopathy syndrome
  - Aseptic meningitis
  - Transverse myelitis
  - ??

Society for Immunotherapy of Cancer
ADVANCES IN Cancer IMMUNOTHERAPY™

Case Studies

Association of Community Cancer Centers

Society for Immunotherapy of Cancer

Case study #1

- 54 year old male with NSCLC

- New immunotherapy treatment initiated 8 weeks ago
- Vision is blurry & sight correction no longer helps
  - Denies eye pain
  - Mild headache “because he reads a lot & his glasses don’t work anymore”
- Exam
  - VA w/o correction: 20/25 right eye (OD), 20/125 left eye (OS)
  - IOP: 10 mmHg OD, 12 mmHg OS
  - Pupils: 5 → 3 mm in both eyes (OU)
  - Confrontation visual fields: temporal loss OD, central scotoma OS

Case study #1

- 54 year old male with NSCLC

- Plan
  - Imaging?
    - CT/MRI
  - Labs?
    - ACTH, TSH, FSH, LH, GH prolactin

Case study #1

- 54 year old male with NSCLC



Case study #1

- 54 year old male with NSCLC

- Treatment
  - Corticosteroids 1 mg/kg/day
  - IV dexamethasone 6mg Q6hr x 3 days
  - Methylprednisolone 125mg daily
  - Switch to oral prednisone after improvement
    - 1-2 mg/kg qd
  - Contact Hem/Onc ASAP

Case study #2

- 45 year old male with NSCLC

- Receiving anti-PD-1 nivolumab for NSCLC
- Diagnosed with hypertension and diabetes
- Symptoms
  - Diffuse abdominal pain for one day
  - Watery, non-bloody diarrhea for three days, >6 stools/day
- Physical Exam
  - Soft, diffuse, mild to moderate abdominal tenderness
  - No rebound or guarding
  - Guaic negative

Case study #2

- 45 year old male with NSCLC

- Plan
  - Contact primary care physician/onc
  - Imaging?
    - CT scan
  - Labs?
    - Stool studies

Case study #2

- 45 year old male with NSCLC

- Diagnosis
  - CT results: Diffuse colitis
  - Stool results: parasites, *C. diff* present

- Treatment
  - Hydration
  - Anagelsia, anti-emetics
  - Antibiotics
  - Steroids

sitc Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

Further resources

Puzanov *et al. Journal for ImmunoTherapy of Cancer* (2017) 5:95
DOI 10.1186/s40425-017-0300-z

Journal for ImmunoTherapy of Cancer

POSITION ARTICLE AND GUIDELINES **Open Access**

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

I. Puzanov[1†], A. Diab[2†], K. Abdallah[3], C. O. Bingham III[4], C. Brogdon[5], R. Dadu[2], L. Hamad[1], S. Kim[2], M. E. Lacouture[6], N. R. LeBoeuf[7], D. Lenihan[8], C. Onofrei[9], V. Shannon[2], R. Sharma[1], A. W. Silk[12], D. Skondra[10], M. E. Suarez-Almazor[2], Y. Wang[2], K. Wiley[11], H. L. Kaufman[12†], M. S. Ernstoff[1*†] and on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group

ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

Bibliography

- Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. *Translational Lung Cancer Research*. 2015;4(5):560-575. doi:10.3978/j.issn.2218-6751.2015.06.06.
- Abdel-Wahab N, Shah M, Suarez-Almazor M. Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. *PLOS*. 2016.07.29.
- Jeffrey S. Weber, Katharina C. Kähler, and Axel Hauschild. Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab. *Journal of Clinical Oncology* 2012 30:21, 2691-2697
- Horvat T, Adel N, et al. Immune-Related Adverse Events, Need for systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients with Melanoma Treated with Ipilimumab at MSKCC. *Journal of Clinical Oncology* 33, no. 28 (October 2015) 3193-3198.
- Images provided under license by adobe stock